Advertisement

Contemporary Review of Peyronie’s Disease Treatment

  • Edward Capoccia
  • Laurence A. Levine
Andrology and Infertility (L Lipshultz, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Andrology and Infertility

Abstract

Purpose

To analyze the literature on the current treatment options for Peyronie’s disease (PD).

Recent Findings

Intracavernosal injection therapy using collagenase clostridium histolyticum (CCH) has been widely adopted since its FDA approval in 2013. Based on the current evidence, it appears to be moderately efficacious for men with mild curvatures. Although a recent study has shown similar outcomes using a modified protocol requiring fewer injections, CCH remains an expensive medication. Surgery provides the most definitive treatment. The most common adverse effect following surgery is perceived loss of length. Length restoration procedures have recently been developed to address this with promising results reported in small series.

Summary

There are a variety of medical treatment options for PD, with CCH getting the most attention for being the first drug to be FDA approved for PD treatment. It is the authors’ opinion that the non-surgical therapy most likely to provide meaningful results is combination therapy utilizing oral, intralesional, and external traction therapy. Surgery remains the gold standard for definitive treatment.

Keywords

Infertility Andrology Peyronie’s disease Treatment Intracavernosal injection therapy 

Notes

Compliance with Ethical Standards

Conflict of Interest

Edward Capoccia declares no potential conflicts of interest.

Laurence A. Levine reports consultant and speaker fees from Boston Scientific and Coloplast.

Human and Animal Rights

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    De la Peyronie F. Sur quelques obstacles quis opposent a l ejaculation naturelle de la semence. Mem Acad Roy Chir. 1743;1:423–34.Google Scholar
  2. 2.
    Smith BH. Peyronie’s disease. Am J Clin Pathol. 1966;45:670–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Rosen R, Catania J, Lue T, Althof S, Henne J, Hellstrom W, et al. Impact of Peyronie's disease on sexual and psychosocial functioning: qualitative findings in patients and controls. J Sex Med. 2008;5:1977–84.CrossRefPubMedGoogle Scholar
  4. 4.
    • Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie’s disease: results of a large survey. BJU Int. 2001;88(7):727–30. This was the first large cross-sectional study evaluating the prevalence of PD. The results helped demonstrate how PD is more widespread than previously thought. CrossRefPubMedGoogle Scholar
  5. 5.
    Ostrowski KA, Gannon JR, Walsh TJ. A review of the epidemiology and treatment of Peyronie's disease. Res Rep Urol. 2016;8:61–70.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Campbell J, Alzubaidi R. Understanding the cellular basis and pathophysiology of Peyronie's disease to optimize treatment for erectile dysfunction. Transl Androl Urol. 2017;6(1):46–59.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    El-Sakka AI, Salabas E, Dinçer M, Kadioglu A. The pathophysiology of Peyronie’s disease. Arab Journal of Urology. 2013;11(3):272–7.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Shaw EJ, Mitchell GC, Tan RB, Sangkum P, Hellstrom WJ. The non-surgical treatment of peyronie disease: 2013 update. World J Mens Health. 2013;31(3):183–92.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ralph D, Gonzalez-cadavid N, Mirone V, et al. The management of Peyronie’s disease: evidence-based 2010 guidelines. J Sex Med. 2010;7(7):2359–74.CrossRefPubMedGoogle Scholar
  10. 10.
    • Nehra A, Alterowitz R, Culkin DJ, et al. Peyronie's Disease: AUA Guideline. J Urol. 2015;194(3):745–53. A systematic review of the literature regarding the diagnosis and treatment of PD. Based on the review, guideline statements were created to help Urologists make evidence based decisions when treating patients with PD. CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Scott WW, Scardino PA. A new concept in the treatment of Peyronie’s disease. South Med J. 1948;41:173–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Sikka SC, Hellstrom WJ. Role of oxidative stress and antioxidants in Peyronie’s disease. Int J Impot Res. 2002;14(5):353–60.CrossRefPubMedGoogle Scholar
  13. 13.
    Paulis G, Brancato T, D'ascenzo R, et al. Efficacy of vitamin E in the conservative treatment of Peyronie's disease: legend or reality? A controlled study of 70 cases. Andrology. 2013;1(1):120–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Zarafonetis CJ, Horrax TM. Treatment of Peyronie's disease with potassium Para-aminobenzoate (potaba). J Urol. 1959;81:770–2.CrossRefPubMedGoogle Scholar
  15. 15.
    Roy J, Carrier S. Acute hepatitis associated with treatment of Peyronie's disease with potassium Para-aminobenzoate (Potaba). J Sex Med. 2008;5(12):2967–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005;47(4):530–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Paulis G, Brancato T. Inflammatory mechanisms and oxidative stress in Peyronie's disease: therapeutic “rationale” and related emerging treatment strategies. Inflamm Allergy Drug Targets. 2012;11(1):48–57.CrossRefPubMedGoogle Scholar
  18. 18.
    Ralph DJ, Brooks MD, Bottazzo GF, et al. The treatment of Peyronie's disease with tamoxifen. Br J Urol. 1992;70:648–51.  https://doi.org/10.1111/j.1464-410X.1992.tb15836.CrossRefPubMedGoogle Scholar
  19. 19.
    Teloken C, Rhoden EL, Grazziotin TM, Ros CT, Sogari PR, Souto CA. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol. 1999;162(6):2003–5.CrossRefPubMedGoogle Scholar
  20. 20.
    El-sakka AI, Bakircioglu ME, Bhatnagar RS, Yen TS, Dahiya R, Lue TF. The effects of colchicine on a Peyronie’s-like condition in an animal model. J Urol. 1999;161(6):1980–3.CrossRefPubMedGoogle Scholar
  21. 21.
    Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study. Int J Impot Res. 2004;16(3):238–43.CrossRefPubMedGoogle Scholar
  22. 22.
    Prieto castro RM, Leva vallejo ME, Regueiro lopez JC, Anglada curado FJ, Alvarez kindelan J, Requena tapia MJ. Combined treatment with vitamin E and colchicine in the early stages of Peyronie's disease. BJU Int. 2003;91(6):522–4.CrossRefPubMedGoogle Scholar
  23. 23.
    Calò LA, Pagnin E, Davis PA, Semplicini A, Nicolai R, Calvani M, et al. Antioxidant effect of L-carnitine and its short chain esters: relevance for the protection from oxidative stress related cardiovascular damage. Int J Cardiol. 2006;107(1):54–60.CrossRefPubMedGoogle Scholar
  24. 24.
    Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int. 2001;88(1):63–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. J Urol. 2007;178(4 Pt 1):1398–403.CrossRefPubMedGoogle Scholar
  26. 26.
    Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-cadavid NF. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide. 2003;9(4):229–44.CrossRefPubMedGoogle Scholar
  27. 27.
    Abern MR, Larsen S, Levine LA. Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie's disease. J Sex Med. 2012;9(1):288–95.CrossRefPubMedGoogle Scholar
  28. 28.
    Griffith RS, Delong DC, Nelson JD. Relation of arginine-lysine antagonism to herpes simplex growth in tissue culture. Chemotherapy. 1981;27(3):209–13.CrossRefPubMedGoogle Scholar
  29. 29.
    Smith JF, Shindel AW, Huang YC, Clavijo RI, Flechner L, Breyer BN, et al. Pentoxifylline treatment and penile calcifications in men with Peyronie's disease. Asian J Androl. 2011;13(2):322–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Safarinejad MR, Asgari MA, Hosseini SY, Dadkhah F. Retraction statement: a double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease. BJU Int. 2015;115(3):E10.CrossRefPubMedGoogle Scholar
  31. 31.
    Raetsch C, Jia JD, Boigk G, et al. Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut. 2002;50(2):241–7.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-cadavid NF. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast cultures. Nitric Oxide. 2003;9(4):229–44.CrossRefPubMedGoogle Scholar
  33. 33.
    Palmieri A, Imbimbo C, Creta M, Verze P, Fusco F, Mirone V. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl. 2012;35(2):190–5.CrossRefPubMedGoogle Scholar
  34. 34.
    Talbert RL, Easterling WJ, Fitch W. Re: transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol. 2005;173(5):1830.CrossRefPubMedGoogle Scholar
  35. 35.
    Twidwell J, Levine LA. Topical treatment for acute phase Peyronie’s disease utilizing a new gel, H-100: a randomized, prospective, placebo controlled pilot study. Int J Impot Res. 2015;28:41–5.  https://doi.org/10.1038/ijir.2015.22.CrossRefPubMedGoogle Scholar
  36. 36.
    Fitch WP 3rd, Easterling WJ, Talbert RL, Bordovsky MJ, Mosier M. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease--a placebo-controlled pilot study. J Sex Med. 2007;4:477–84.CrossRefPubMedGoogle Scholar
  37. 37.
    Lee RC, Ping JA. Calcium antagonists retard extracellular matrix production in connective tissue equivalent. J Surg Res. 1990;49(5):463–6.17367443.CrossRefPubMedGoogle Scholar
  38. 38.
    Fitch WP, Easterling WJ, Talbert RL, Bordovsky MJ, Mosier M. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease--a placebo-controlled pilot study. J Sex Med. 2007;4(2):477–84.CrossRefPubMedGoogle Scholar
  39. 39.
    Levine LA, Estrada CR, Shou W, Cole A. Tunica albuginea tissue analysis after electromotive drug administration. J Urol. 2003;169(5):1775–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie’s disease: a double-blind, placebo controlled trial. J Urol. 2007;177(3):972–5.CrossRefPubMedGoogle Scholar
  41. 41.
    Levine LA, Goldman KE, Greenfield JM. Experience with intraplaque injection of verapamil for Peyronie’s disease. J Urol. 2002;168:621–5.CrossRefPubMedGoogle Scholar
  42. 42.
    Shirazi M, Haghpanah AR, Badiee M, Afrasiabi MA, Haghpanah S. Effect of intralesional verapamil for treatment of Peyronie’s disease: a randomized single-blind, placebo-controlled study. Int Urol Nephrol. 2009;41(3):467–71.CrossRefPubMedGoogle Scholar
  43. 43.
    Levine LA, Estrada CR. Intralesional verapamil for the treatment of Peyronie’s disease: a review. Int J Impot Res. 2002;14(5):324–8.CrossRefPubMedGoogle Scholar
  44. 44.
    Larsen SM, Levine LA. Review of non-surgical treatment options for Peyronie’s disease. Int J Impot Res. 2012;24:1–10.CrossRefPubMedGoogle Scholar
  45. 45.
    Demey A, Chevallier D, Bondil P, Toubol J, Amiel J. Is intracavernosal corticosteroid infiltration really useless in Peyronie’s disease? Prog Urol. 2006;16(1):52–7.PubMedGoogle Scholar
  46. 46.
    Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, −beta and -gamma. Scand J Urol Nephrol. 1991;25(2):89–94.CrossRefPubMedGoogle Scholar
  47. 47.
    Hellstrom WJ, Kendirci M, Matern R, et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie’s disease. J Urol. 2006;176(1):394–8.CrossRefPubMedGoogle Scholar
  48. 48.
    Trost LW, Ates E, Powers M, Sikka S, Hellstrom WJG. Outcomes of intralesional interferon-α2B for the treatment of Peyronie’s disease. J Urol. 2013;190:2194–9.CrossRefPubMedGoogle Scholar
  49. 49.
    Gelbard M, Hellstrom WJ, McMahon CG, et al. Baseline characteristics from an ongoing phase 3 study of collagenase clostridium histolyticum in patients with Peyronie’s disease. J Sex Med. 2013;10:2822–31.CrossRefPubMedGoogle Scholar
  50. 50.
    Watt AJ, Hentz VR. Collagenase clostridium histolyticum: a novel nonoperative treatment for Dupuytren’s disease. Int J Clin Rhematol. 2011;6:123–33.CrossRefGoogle Scholar
  51. 51.
    Gelbard M, Goldstein I, Hellstrom WJ, et al. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199–207.CrossRefPubMedGoogle Scholar
  52. 52.
    Lipshultz L, Goldstein I, Seftel A, et al. Clinical efficacy of collagenase clostridium histolyticum in the treatment of Peyronie’s disease by subgroups: results from two large, double-blind, randomized, placebo-controlled, phase 3 studies. BJU Int. 2015;116:650–6.CrossRefPubMedGoogle Scholar
  53. 53.
    Ziegelmann MJ, Viers BR, Mcalvany KL, Bailey GC, Savage JB, Trost LW. Restoration of penile function and patient satisfaction with Intralesional collagenase clostridium histolyticum injection for Peyronie’s disease. J Urol. 2016;195(4 Pt 1):1051–6.CrossRefPubMedGoogle Scholar
  54. 54.
    Yang KK, Bennett N. Peyronie's disease and injectable collagenase clostridium histolyticum: safety, efficacy, and improvements in subjective symptoms. Urology. 2016;94:143–7.CrossRefPubMedGoogle Scholar
  55. 55.
    • Abdel raheem A, Johnson M, Abdel-raheem T, Capece M, Ralph D. Collagenase Clostridium histolyticum in the Treatment of Peyronie's Disease-A Review of the Literature and a New Modified Protocol. Sex Med Rev. 2017;5(4):529–35. Prospective study of 53 men with PD treatment with CCH using a modified protocol. The results showed the new shortened protocol to provide similar results compared to standard protocol with a significant decrease in cost and time commitment. CrossRefPubMedGoogle Scholar
  56. 56.
    • Cordon BH, Hofer MD, Hutchinson RC, Broderick GA, Lotan Y, Morey AF. Superior cost effectiveness of penile plication vs intralesional collagenase injection for treatment of Peyronie’s disease deformities. Urol Pract. 2017;4(2):118–25. A cost analysis was performed comparing CCH and penile plication. The average cost of plication surgery was $3,039 compared to $25,856 for a treatment course of CCH. CrossRefGoogle Scholar
  57. 57.
    Masuko K, Murata M, Yudoh K, Kato T, Nakamura H. Anti-inflammatory effects of hyaluronan in arthritis therapy: not just for viscosity. Int J Gen Med. 2009;2:77–81.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Zucchi A, Costantini E, Cai T, et al. Intralesional injection of hyaluronic acid in patients affected with Peyronie’s disease: preliminary results from a prospective, multicenter, pilot study. Sex Med. 2016;4(2):e83–8.PubMedGoogle Scholar
  59. 59.
    Palmieri A, Imbimbo C, Longo N, Fusco F, Verze P, Mangiapia F, et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie’s disease. Eur Urol. 2009;56:363–9.CrossRefPubMedGoogle Scholar
  60. 60.
    Chitale S, Morsey M, Swift L, Sethia K. Limited shock wave therapy vs sham treatment in men with Peyronie’s disease: results of a prospective randomized controlled doubleblind trial. BJU Int. 2010;106:1352–6.CrossRefPubMedGoogle Scholar
  61. 61.
    Hatzichristodoulou G, Meisner C, Gschwend JE, Stenzl A, Lahme S. Extracorporeal shock wave therapy in Peyronie’s disease: results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med. 2013;10(11):2815–21.CrossRefPubMedGoogle Scholar
  62. 62.
    Chung E. Pro: does shockwave therapy have a place in the treatment of Peyronie’s disease? Transl Androl Urol. 2016;5(3):366–70.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Mulhall JP, Hall M, Broderick GA, Incrocci L. Radiation therapy in Peyronie’s disease. J Sex Med. 2012;9(5):1435–41.CrossRefPubMedGoogle Scholar
  64. 64.
    Chung E, De young L, Solomon M, Brock GB. Peyronie’s disease and mechanotransduction: an in vitro analysis of the cellular changes to Peyronie’s disease in a cell-culture strain system. J Sex Med. 2013;10(5):1259–67.CrossRefPubMedGoogle Scholar
  65. 65.
    • Martinez-Salamanca JI, Equi A, Moncada I, et al. Acute phase Peyronie’s disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation. J Sex Med. 2014;11:506–15. 55 men underwent 6 months of PTT and were compared to 41 men who underwent no treatment. All men were in the active phase. Men who underwent PTT had a significant improvement in their curvature and erectile function when compared to the control group. CrossRefPubMedGoogle Scholar
  66. 66.
    Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie’s disease: a single-center pilot study. J Sex Med. 2008;5:1468–73.CrossRefPubMedGoogle Scholar
  67. 67.
    Levine AL, Larsen SM. Surgery for Peyronie's disease. Asian J Androl. 2013;15:27–34.CrossRefPubMedGoogle Scholar
  68. 68.
    Ostrowski KA, Gannon JA, Walsh TJA. Review of the epidemiology and treatment of Peyronie’s disease. Res Rep Urol. 2016;29:61–70.Google Scholar
  69. 69.
    Levine LA, Lenting EL. A surgical algorithm for the treatment of Peyronie’s disease. J Urol. 1997;158(6):2149–52.CrossRefPubMedGoogle Scholar
  70. 70.
    Levine LA, Dimitriou RJ. A surgical algorithm for penile prosthesis placement in men with erectile failure and Peyronie's disease. Int J Impot Res. 2000;12(3):147–51.CrossRefPubMedGoogle Scholar
  71. 71.
    Andrews HO, al-Akraa M, Pryor JP, Ralph DJ. The Nesbit operation for congenital curvature of the penis. Int J Impot Res. 1999;11:119–22.CrossRefPubMedGoogle Scholar
  72. 72.
    Yachia D. Corporeal plication for surgical correction of Peyronie’s disease. J Urol. 1993;149:869.CrossRefPubMedGoogle Scholar
  73. 73.
    Brant WO, Bella AJ, Lue TF. 16-dot procedure for penile curvature. J Sex Med. 2007;2:277–80.CrossRefGoogle Scholar
  74. 74.
    Levine LA. Penile straightening with tunica albuginea plication procedure: TAP procedure. In: Levine LA, editor. Peyronie’s disease: a guide to clinical management Totowa, NJ; Humana; 2006. p. 151–60.Google Scholar
  75. 75.
    Ding S, Lu J, Zhang H, et al. A novel modification of tunical plication by plaque thinning: long-term results in treating penile curvature of Peyronie's disease. Int Urol Nephrol. 2010;42:597–602.CrossRefPubMedGoogle Scholar
  76. 76.
    Papagiannopoulos D, Phelps J, Yura E, Levine LA. Surgical outcomes from limiting the use of nonabsorbable suture in tunica albuginea plication for Peyronie's disease. Int J Impot Res. 2017;29(6):258–61.CrossRefPubMedGoogle Scholar
  77. 77.
    Van Der Horst C, Martinez Portillo FJ, Seif C, et al. Treatment of penile curvature with Essed-Schroder tunical plication: aspects of quality of life from the patients’ perspective. BJU Int. 2004;93:105–8.CrossRefGoogle Scholar
  78. 78.
    Sherer BA, Levine LA. Contemporary review of treatment options for Peyronie’s disease. Urology. 2016;95:16–24.CrossRefPubMedGoogle Scholar
  79. 79.
    Taylor FL, Levine LA. Surgical correction of Peyronie’s disease via tunica albuginea plication or partial plaque excision with pericardial graft: long-term follow up. J Sex Med. 2008;5:2221–8.CrossRefPubMedGoogle Scholar
  80. 80.
    Levine LA. Partial plaque excision and grafting (PEG) for Peyronie’s disease. J Sex Med. 2011;8:1842–5.CrossRefPubMedGoogle Scholar
  81. 81.
    Rybak J, Papagiannopoulos D, Levine L. A retrospective comparative study of traction therapy vs. no traction following tunica albuginea plication or partial excision and grafting for Peyronie’s disease: measured lengths and patient perceptions. J Sex Med. 2012;9:2396–403.CrossRefPubMedGoogle Scholar
  82. 82.
    Usta MF, Bivalacqua TJ, Sanabria J, Koksal IT, Moparty K, Hellstrom WJG. Patient and partner satisfaction and long-term results after surgical treatment for Peyronie's disease. Urology. 2003;62:105–9.CrossRefPubMedGoogle Scholar
  83. 83.
    Montorsi F, Salonia A, Maga T, et al. Evidence based assessment of long-term results of plaque incision and vein grafting for Peyronie's disease. J Urol. 2000;163:1704–8.CrossRefPubMedGoogle Scholar
  84. 84.
    Wilson SK, Delk JR. A new treatment for Peyronie’s disease: modeling the penis over an inflatable penile prosthesis. J Urol. 1994;152:1121–3.CrossRefPubMedGoogle Scholar
  85. 85.
    Montague DK. Penile prosthesis implantation: size matters. Eur Urol. 2007;51(4):887–8.CrossRefPubMedGoogle Scholar
  86. 86.
    Rolle L, Ceruti C, Timpano M, Sedigh O, Destefanis P, Galletto E, et al. A new, innovative, lengthening surgical procedure for Peyronie’s disease by penile prosthesis implantation with double dorsal-ventral patch graft: the “sliding technique”. J Sex Med. 2012;9(9):2389–95.CrossRefPubMedGoogle Scholar
  87. 87.
    • Morey AF. Re: Penile lengthening and widening without grafting according to a modified ‘sliding’ technique. J Urol. 2016;195(6):1822–3. A modified sliding technique was performed on 143 patients to determine the feasibility and safety of this length and girth restoring procedure. The authors reported a mean length gain of 3.1 cm. Google Scholar
  88. 88.
    • Wilson SK, Mora-estaves C, Egydio P, et al. Glans necrosis following penile prosthesis implantation: prevention and treatment suggestions. Urology. 2017;107:144–8. Examined 21 patients who had glans necrosis following penile prosthesis implantation to better determine the etiology. Risk factors for glans necrosis include cardiovascular disease, diabetes, using sliding technique, and subcoronal incision. CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Rush University Medical CenterChicagoUSA

Personalised recommendations